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Abstract 
Beta secretase (BACE) inhibitors are promising therapeutic compounds currently in clinical phase II/III trials. 
Preclinical [18F]-florbetaben (FBB) amyloid PET imaging facilitates longitudinal monitoring of amyloidosis in 
Alzheimer’s disease (AD) mouse models. Therefore, we applied this theranostic concept to investigate, by 
serial FBB PET, the efficacy of a novel BACE1 inhibitor in the PS2APP mouse, which is characterized by early 
and massive amyloid deposition. 
Methods: PS2APP and C57BL/6 (WT) mice were assigned to treatment (PS2APP: N=13; WT: N=11) and 
vehicle control (PS2APP: N=13; WT: N=11) groups at the age of 9.5 months. All animals had a baseline PET 
scan and follow-up scans at two months and after completion of the four-month treatment period. In addition 
to this longitudinal analysis of cerebral amyloidosis by PET, we undertook biochemical amyloid peptide 
quantification and histological amyloid plaque analyses after the final PET session. 
Results: BACE1 inhibitor-treated transgenic mice revealed a progression of the frontal cortical amyloid signal 
by 8.4 ± 2.2% during the whole treatment period, which was distinctly lower when compared to vehicle-treated 
mice (15.3 ± 4.4%, p<0.001). A full inhibition of progression was evident in regions with <3.7% of the increase 
in controls, whereas regions with >10% of the increase in controls showed only 40% attenuation with BACE1 
inhibition. BACE1 inhibition in mice with lower amyloidosis at treatment initiation showed a higher efficacy in 
attenuating progression to PET. A predominant reduction of small plaques in treated mice indicated a main 
effect of BACE1 on inhibition of de novo amyloidogenesis. 
Conclusions: This theranostic study with BACE1 treatment in a transgenic AD model together with amyloid 
PET monitoring indicated that progression of amyloidosis is more effectively reduced in regions with low initial 
plaque development and revealed the need of an early treatment initiation during amyloidogenesis. 
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Introduction 
Alzheimer’s disease (AD) is the most common 
form of neurodegenerative dementia, and has an 
enormous impact on societies with aging populations 
[1]. The core histopathological features for diagnosis 
of AD consist of neurofibrillary tangles and amyloid 
plaques [2], which can now be assessed by molecular 
imaging in vivo [3, 4]. The principal component of 









heterogeneous cleavage product of the β-amyloid 
precursor protein (APP). After initial ectodomain 
shedding of APP by the β-site amyloid precursor 
protein cleaving enzyme 1 (BACE1), which has many 
other known physiological substrates, the remaining 
APP C-terminal fragment (CTF-β) is subsequently 
cleaved by the intramembrane protease γ-secretase, 
thereby releasing free Aβ. Alternately, the smaller 
peptide fragment p3 is released following shedding 
by ADAM10. Additional fragments are formed via the 
η-secretase ectodomain shedding pathway, which is 
followed by a BACE1 or an ADAM10 cleavage to 
produce longer (Aη-α) or shorter (Aη-β) forms of the 
native Aη peptide [5]. However, the rate limiting step 
for production of the Aβ peptide is the activity of the 
β-secretase enzyme, which is widely considered to 
have a crucial role in the initiation of AD pathology. 
Current symptomatic therapeutic options for AD 
include acetylcholinesterase inhibitors [6] and NMDA 
receptor antagonists [7], both of which provide some 
transient amelioration of cognitive symptoms, but 
without any disease-modifying effects [8, 9]. With the 
advent of highly potent and BBB-permeable inhibitors 
of BACE1, this enzyme has emerged as a primary 
drug target for reducing Aβ deposition in the AD 
brain. Therefore, the development and in vivo 
characterization of BACE1 inhibitors as therapeutic 
agents is of highest interest, with the caveat that 
untoward side effects can occur because of the wide 
spectrum of identified BACE1 substrates, especially in 
the central nervous system [10]. Most of the hitherto 
available BACE1 inhibitors also block the activity of 
BACE2, a close homologue of BACE1, which may 
cause additional on-target side effects [11]. 
Nonetheless, several BACE1 inhibitors are in human 
clinical trials testing for efficacy and safety in 
individuals with pre-symptomatic or manifest AD 
[12]. However, these trials have not so far imparted 
cognitive improvement in AD patients, indicating the 
necessity of much earlier and sustained BACE1 
inhibitor treatment to efficiently prevent the 
accumulation of Aβ in the brain [13].  
Amyloid positron-emission-tomography (PET) 
has in recent years emerged as valuable tool for 
assessment of cortical amyloidosis in vivo, and has 
been designated as a gatekeeper for inclusion of 
patients in anti-amyloid treatment trials. For such 
trials it is crucial to determine the dose-response of 
BACE1 inhibition and to define the optimal stage of 
AD for initiation of effective intervention with specific 
BACE1 inhibitors [12]. By the same measure, Aβ-PET 
also serves as a non-invasive tool for monitoring the 
amyloid plaque burden in transgenic mice, yielding 
excellent correlations with histological or biochemical 
assessments [14-16]. In this regard, longitudinal 
preclinical trials of BACE1 inhibition using Aβ-PET as 
an endpoint are of great translational value, and are 
readily validated by ex vivo histological examinations. 
As in clinical studies, baseline Aβ-PET results can be 
used to construct comparable experimental animal 
groups, and to investigate preconditions for 
individual differences in the progression of pathology 
longitudinally [15].  
Given this background, we aimed to apply a 
theranostic concept for monitoring by 
[18F]-florbetaben Aβ-PET the progression of 
amyloidosis in living PS2APP mice treated for four 
months with the small molecule BACE1 inhibitor 
RO5508887 [17]. We used serial and regional PET 
analyses for identifying the determinants of efficacy 
of BACE1 inhibition. Multimodal histological and 
biochemical readouts obtained post mortem served to 




Groups of 26 female PS2APP-Swe (TG) and 22 
female C57BL/6 (WT) mice were randomly assigned 
to either treatment (TG-BSI; WT-BSI) or vehicle 
(TG-VEH; WT-VEH) groups at the age of 9.5 months. 
A baseline [18F]-florbetaben-PET scan (Aβ-PET) was 
performed at this time, followed by initiation of daily 
oral RO5508887 treatment or vehicle, for a period of 
four months. Follow-up Aβ-PET-scans were acquired 
after 10 weeks (at 11.5 months of age), and 18.5 weeks 
of treatment (at 13.5 months of age), whereupon the 
study was terminated. An additional pre-baseline PET 
scan at 8 months (-6 weeks) had been performed to 
investigate the natural longitudinal Aβ deposition 
rates in all mice prior to their randomization. Thus, 
each mouse underwent a total of four 
[18F]-florbetaben-PET scans over a period of 18 weeks. 
After completing the final scan, mice were killed and 
the brains removed for histological and biochemical 
analyses. Dose-titration experiments had been 
conducted prior to the chronic treatment in a separate 
group of 24 PS2APP mice. Figure 1 illustrates the 
study design. 
Animals  
All experiments were performed in compliance 
with the National Guidelines for Animal Protection, 
Germany, with approval of the local animal care 
committee (Regierung Oberbayern), and overseen by 
a veterinarian. The transgenic B6.PS2APP (line 
B6.152H) mouse is homozygous for both the human 
presenilin (PS) 2, N141I mutation and the human 
amyloid precursor protein (APP) K670N, M671L 
mutation. The APP and PS2 transgenes are driven by 





mouse Thy-1 and mouse prion promoters, 
respectively. This line had been created by 
co-injection of both transgenes into C57BL/6 zygotes 
[18]. Homozygous B6.PS2APP mice show first 
appearance of amyloid plaques in the cortex and 
hippocampus at only five to six months of age [19]. 
BACE1 inhibitor 
The previously evaluated BACE1 inhibitor 
RO5508887 was used at a defined dose of 100 
mg/kg/d, which proved to be suitable in the chronic 
treatment arm of the same evaluation study using 
APPV717I transgenic mice [17]. Treatment was 
performed orally two times per day (11-13 h apart) 
per os (gavage). Acute in vivo treatment was 
performed for a dose finding in the PS2APP-Swe 
transgenic mouse model (N=24) with mutations 
causing increased BACE1 affinity and higher 
substrate turnover compared to normal APP, where 
RO5508887 proved to substantially block the enzyme 
at an acute dose of 30 mg/kg [17]. Therefore, the 
compound was administered once per os in 
PS2APP-Swe mice (60/90/120 mg/kg). For 
comparison, control PS2APP-Swe mice were treated 
with vehicle only (that is: 5% ethanol (VWR, 
Germany), 10% Solutol (MilliporeSigma, Germany) 
dissolved in sterile water). Brains were collected 2 and 
4 h after acute treatment and stored at -80 °C until 
analysis. Two mice were used per time-point and 
dose/vehicle. DEA and RIPA lysates served to 
monitor the changes in BACE1-dependent APP 
processing affecting the levels of soluble Aβ as 
measured by Western blot analysis (Figure S1). 
Aβ-PET 
Aβ-PET image acquisition, reconstruction and 
analysis followed a standardized protocol, as 
previously published [14, 16, 20], with some 
refinements and adaptions as described in detail in 
Supplementary Material. After measuring tracer 
uptake in cerebral cortex and white matter templates, 
standardized-uptake-value-ratios (SUVRCTX/WM) 
values were calculated for all groups of mice at each 
Aβ-PET scan timepoint. Individual longitudinal 
changes were calculated as a function of time (Δ%- 
SUVRCTX/WM). 
Regional deposition rates were assessed by 
voxel-wise PET analyses. To this end, mean 
parametric images (SUVRWM) were calculated for the 
TG-BSI and TG-VEH groups at each time point (N 
=12-13 mice). The %-difference images were obtained 
by parametric image algebra in PMOD ((Timepoint-2 
– Timepoint-1)/Timepoint-1 × 100%). Next, the 
%-difference map of vehicle-treated animals between 
baseline and terminal PET scan was used for defining 
volumes-of-interest (VOIs) depicting 2%-stepwise 
increments of Aβ deposition rate over the 18.5 weeks 
of treatment. Adjacent 2%-step VOIs were combined 
to define regions of low (2-10%) and high (>10%) 
amyloid deposition rates.  
Biochemistry 
Aβ extraction from brain and quantification 
Brains were removed from the cranium and 
dissected into left and right hemispheres. One 
randomly selected hemisphere was snap-frozen by 
immersion in liquid nitrogen and stored at –80 °C. 
Soluble proteins were extracted with DEA buffer (50 
mM NaCl, 0.2 % diethylamine, pH 10 + protease 
inhibitor (P8340, Sigma-Aldrich)). Membrane proteins 
were extracted with RIPA buffer (20 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate + protease inhibitor). RIPA-insoluble 
material was dissolved in 70% formic acid. 
Quantification of Aβ was performed according to the 
manufacturer’s protocol using the MSD® 
 
Figure 1. Illustration of the study design. PS2APP (TG) and WT mice were scanned by Aβ-PET starting at 8 months of age (Time-point (TP) -6). Treatment/vehicle 
randomization was realized after the 9.5 month scan (TP 0). Shortly after the terminal scan at 13.5 months (TP +18.5) all brains were split after perfusion and randomized 
hemispheres were used for terminal immunohistochemistry (methoxy-X04 plaque staining) and biochemistry analyses (protein assays). 
 





MULTI-SPOT Human (6E10) Aβ Triplex Assay (Meso 
Scale Diagnostics, Rockville, USA) with a MSD 
SECTOR Imager 4200. Quantitative data were 
analyzed statistically by two-tailed Student’s t-test (N 
=12 mice). 
Protein analysis 
Proteins were separated under denaturing 
conditions using discontinuous SDS-PAGE. Equal 
amounts of proteins denatured in Laemmli buffer 
were loaded onto the gel and 10 µL portions of the 
SeeBlue Plus2 Prestained Standard (Invitrogen) 
served as a molecular weight marker. Electrophoresis 
was performed in Tris-glycine buffer (25 mM Tris, 190 
mM glycine in ddH2O) using the Mini-PROTEAN 
system (BIORAD) on activated PVDF membranes. 
Low molecular weight proteins (< 20 kDa) were 
separated using precast gradient Tricine Protein Gels 
(10-20%, 1 mm, Novex) in Tris-tricine buffer using the 
XCell SureLock Mini-Cell system (Novex). After 
separation by SDS-PAGE, proteins were transferred 
onto membranes using the tank/wet Mini Trans-Blot 
cell system (BIORAD). CTFs, Aη and Aβ were 
detected after transfer on Nitrocellulose membranes 
(Protran BA85; GE Healthcare), while other proteins 
were blotted on PVDF (Immobilon-P, Merck 
Millipore). Upon completion of the transfer and prior 
to blocking, proteins transferred to nitrocellulose 
membranes were additionally denatured by boiling 
the membranes in PBS (140 mM NaCl, 10 mM 
Na2HPO4, 1.75 mM KH2PO4, 2.7 mM KCl in ddH2O, 
pH 7.4) for 5 min. After cooling to room temperature, 
the nitrocellulose membranes as well as the PVDF 
membranes were blocked in I-Block solution (0.2% 
Tropix I-Block (Applied Biosystems) in PBS-T (0.1% 
Tween20 in PBS) for 1 h at room temperature or 
overnight at 4 °C (with agitation). Transferred 
proteins were detected using immunodetection and 
enhanced chemiluminescence (ECL). First, blocked 
membranes were incubated with primary antibodies 
diluted in I-Block solution overnight at 4 °C (with 
agitation). After removal of the antibody, membranes 
were washed 3x in PBS-T buffer (10 min each, at room 
temperature, with agitation) and subsequently 
incubated with a horseradish peroxidase 
(HRP)-coupled secondary antibody (obtained from 
Santa Cruz Biochemicals). Secondary antibodies were 
diluted in I-Block solution and membranes were 
incubated for 1 h at RT (with agitation) followed by 
three washes in PBS-T. For ECL detection, membranes 
were incubated with HRP substrate (ECL, GE 
Healthcare or ECL Plus, Thermo Scientific) for 1 min 
at RT and signals were captured by exposure of X-ray 
film (Super RX Medical X-Ray, Fujifilm), which were 
subsequently developed using an automated film 
developer (CAWOMAT 2000 IR, CAWO). Signal 
intensities were quantified using ImageJ analysis 
software and plotted as relative differences of the 
treatment group compared to control. 
Antibodies 
DEA soluble protein was analysed for APP 
processing products with the following antibodies: 
22C11 for detecting the APP N-terminus (used at 1 
µg/mL, obtained from MilliporeSigma, Darmstadt, 
Germany), 6A1 for detecting sAPPβ-swe cleaved by 
BACE1 (used at 1 µg/mL; obtained from Tecan/ IBL 
International, Hamburg, Germany). 2D8 is an 
in-house rat monoclonal antibody against the 
N-terminus of Aβ, detecting also Aη-α (used at 2 
µg/mL). 
Histochemical analyses 
Fibrillary β-amyloid plaques in brain specimens 
were stained with the fluorescent dye methoxy-X04 
(0.01 mg/mL in PBS at pH 7.4 for 15 min) [21]. Full 
details are described in Supplementary Material. 
Plaque load was calculated as the summed area of all 
plaques relative to the frontal cortex area. Plaque 
density was calculated as the number of plaques 
relative to frontal cortex volume [20]. These analyses 
were performed by an operator blind to the Aβ-PET 
results. 
Statistics 
Group comparisons of VOI-based Aβ-PET 
results and biochemistry were performed with 
multivariate analysis of variance (MANOVA) using 
IBM SPSS Statistics (Version 23.0). Histology data 
(plaque load and plaque density) were compared 
between treated and untreated transgenic mice by 
multivariate analysis of covariance (MANCOVA) 
using Aβ-PET baseline estimates as a covariate. 
Treatment effects in low and high amyloid 
accumulating regions were compared with a t-test. 
For correlation analyses, Pearson’s coefficients of 
correlation (R) were calculated. Plaque size 
distributions were compared with a Chi-square test 
followed by the Kolmogorov-Smirnov test with Prism 
V5.04 software (GraphPad Software, San Diego, CA, 
USA). A Shapiro-Wilk test was performed to verify 
normal distribution of sample values. A threshold of 
p<0.05 was deemed significant for rejection of the null 
hypothesis. 
Results 
Chronic BACE-I treatment effectively inhibits 
fibrillary Aβ deposition as monitored by PET 
We applied a theranostic concept of longitudinal 
Aβ-PET during chronic BACE-1 inhibition in PS2APP 





mice to study treatment effects over 18.5 weeks and to 
investigate the value of treatment monitoring. 
Multimodal readouts by terminal Aβ peptide level, 
and terminal plaque load to immunohistochemistry 
served for further characterization of the effect of 
chronic treatment with RO5508887 on amyloidosis in 
PS2APP mice. 
Treatment and serial PET imaging proved 
well-tolerated, with only a single dropout in the 
TG-BSI group. All modalities revealed a significantly 
reduced progression of amyloidosis in TG-BSI mice 
when compared to the TG-VEH group. Particularly, 
PET revealed a significantly lower progression of 
amyloidosis as early as 10 weeks into the treatment 
regimen (+6.7% in BSI vs. +10.3% in VEH, p < 0.05) 
and an even greater effect at 18.5 weeks of treatment 
(+8.4% in BSI vs. +15.2% in VEH, p < 0.001; Figure 2). 
WT mice presented with stable PET values either in 
the treatment or the vehicle groups. 
Terminal immunohistochemistry confirmed PET 
findings by the direct validation of fibrillary Aβ and 
indicated lower plaque load (-9.7%, p < 0.05; Figure 
3A) as well as plaque density (-9.9%, p < 0.05; Figure 
3B) in BACE1-treated TG mice when compared to TG 
vehicle controls. The major effect was observed on de 
novo plaque deposition, as the fraction of small 
plaques was apparently lower in the same contrast of 
treated versus control mice (Figure 3C-D). 
Acute and chronic BACE1 treatment lowers 
Aβ deposition  
Brains of the PSAPP2-swe transgenic mice were 
collected 4 h after the last BACE1 inhibitor or vehicle 
treatment to allow monitoring of both the steady-state 
enzyme activity after inhibitor application and the 
long-term effect of the chronic treatment. BACE1 
inhibition results in reduction of the amyloidogenic 
pathway as indicated by lower levels of sAPP-β (Swe) 
and increased sAPP-α, while total sAPP remained 
unchanged. BACE1 inhibition resulted in a clear 
reduction of soluble Aβ and consequently an increase 
of Aη-α in the DEA fraction, which is enriched in 
soluble fragments, of the TG-BSI mice compared to 
TG-VEH controls 4 h after acute treatment (Figures 
4A-B). Furthermore, soluble Aβ (DEA) and deposited 
Aβ (FA) were quantified by ELISA (Figures 4C-D). 
Compared to the TG-VEH group, we saw a 47% 
reduction of soluble Aβ40 and a 61% reduction of 
Aβ42, respectively, in the group treated with the 
BACE inhibitor RO550887 (Figure 4C). However, the 
TG-BSI animals showed only a slight reduction of 
Aβ40 levels (-10% in TG-BSI vs. TG-VEH, p = 0.45), 
but significantly reduced Aβ42 levels after chronic 
treatment over 18 weeks in the fraction of deposited 




Figure 2. Longitudinal Aβ-PET imaging of BACE1 inhibition. (A) Plots show means (±SD) of the cortical amyloid signal relative to the baseline imaging for treated and 
vehicle groups of TG and WT mice. (B) Individual progression of the cortical amyloid signal in TG mice. (C) Signal intensities of the frontal cortical amyloid signal in TG and WT 
mice at the terminal Aβ-PET scan (18.5 weeks). Coronal and axial slices illustrate group averages upon a T1w MRI template. * p < 0.05; *** p < 0.001 






Figure 3. Immunohistochemical validation of Aβ-PET results. Plots show frontal cortical mean (±SD) of plaque load (A) and plaque density (B) by methoxy-X04 
immunohistochemistry in TG-VEH (green) and TG-BSI (red) mice. (C) Histogram plotting of plaque size revealed significantly fewer small plaques in the TG-BSI animals (red) in 
comparison to the TG-VEH group (green), which was also explored in the visual analysis of sagittal cortical slices of methoxy-X04 staining (D). Error bars indicate SD. * p < 0.05. 
 
Figure 4. Biochemical analyses. (A) In Western blots, BACE1 inhibition was observed to result in reduction of the amyloidogenic pathway, as indicated by lowered levels of 
sAPP-β (Swe) and increased sAPP-α levels. The lower panel indicates that BACE1 inhibition caused reduced levels of soluble Aβ and an increase of Aη-α in brains of the TG-BSI 
mice compared to TG-VEH controls 4 h after acute treatment. (B) Quantification of APP processing products indicated significant increase for sAPP-α and Aη-α, but significant 
reduction for the BACE1-dependent products sAPP-β and Aβ, while total sAPP shedding remained unchanged (vehicle (n=6); BI/BACE inhibitor treated (n=5)). (C) Lower DEA 
levels of soluble Aβ40 and Aβ42 were observed in TG-BSI mice relative to TG-VEH controls. (D) Insoluble FA levels likewise indicated a significant reduction of Aβ42, but only 
a small tendency for reduced Aβ40 levels. Error bars indicate SD, * p < 0.05; ** p < 0.005; *** p < 0.001; n.s.= not significant. 





In summary, all readouts and modalities 
indicated a significant chronic treatment effect by 
RO5508887 on progression of amyloidosis in PS2APP 
mice.  
Effectiveness of chronic BACE1 inhibition 
treatment depends on regional Aβ deposition 
rates 
In a separate analysis, we used the theranostic 
Aβ-PET approach to investigate regional longitudinal 
differences in amyloidosis during chronic treatment. 
We aimed to reveal possible relationships between the 
“naïve” regional deposition rate and the subsequent 
regional chronic treatment effect. Individual PET 
results in TG-VEH mice revealed the highest “naïve” 
regional increase in amyloidosis (Δ%-SUVRWM) in the 
bilateral frontal cortex (primary somatosensory areas), 
followed by primary motor areas and auditory and 
visual cortices. Lower progression of amyloidosis was 
observed in temporal cortex areas (e.g., gustatory, 
insular), as well as in the bilateral thalamus and 
hippocampus (Figure S2). 
Interestingly, we found a linear relationship 
(R>0.99; p<0.001) between the regional amyloid 
progression rate in TG-VEH, i.e., naïve progression, 
and the corresponding progression in TG-BSI mice 
(Figure 5A). This relationship indicated a threshold 
for regional deposition rate of 3.7% / 18.5 weeks in 
TG-VEH, below which complete blocking of further 
signal increase could be achieved with RO5508887 
treatment of TG mice. A polynomial function could be 
fitted to a plot of the individual treatment effect 
relative to naïve progression in the TG-VEH group, 
thus revealing very high treatment effect in regions 
with low naïve progression, which declined to a 
trough, with only 40% attenuation of amyloidosis in 
those regions with naïve progression exceeding about 
15% (Figure 5B). This finding was verified by 
voxel-wise mapping of the %-treatment effect, which 
showed the highest relative effect (nearly 100%) of 
BACE1 inhibition in brain regions with inherently low 
Aβ-accumulation (e.g., gustatory and insular areas, 
thalamus; Figure 5C). 
 
 
Figure 5. Analysis of high and low Aβ accumulating regions. (A) Progression of the Aβ-PET signal in TG-VEH (x-axis) against TG-BSI (y-axis) mice. Values were obtained 
from regions with equal Aβ accumulation in TG-VEH mice. Dotted line shows halted fibrillary Aβ accumulation (0%) in TG-BSI mice and the nearly linear correlation of single 
regions between TG-VEH and TG-BSI mice calculates a complete stop of further fibrillary Aβ accumulation in regions of ≤ +3.7% signal increase in TG-VEH. Low and high Aβ 
accumulating regions were defined by 2-10% and > 10% signal increase in TG-VEH mice over 18.5 months. (B) Consecutively, an exponential increase of the treatment effect in 
TG-BSI relative to TG-VEH mice was found with decreasing regional Aβ accumulation, as observed in drug-naïve TG mice. (C) A 3D analysis of the forebrain confirmed these 
findings by indicating the highest relative treatment effect in lateral neocortical brain regions with a low Aβ accumulation. The absolute reduction of the Aβ deposition rate was 
significantly larger in high Aβ accumulating regions (D), whereas the relative therapy effect was significantly lower in high Aβ accumulating regions (E). 





Concerning the absolute reduction in Aβ 
deposition with treatment, we found a decrease of 7.6 
± 1.7% in high accumulating regions (≥ 10%; total 
volume: 77 mm³) and a lesser decrease of 4.8 ± 2.0% in 
low accumulating regions (<10%; total volume: 92 
mm³; p < 0.005, Figure 5D). However, the relative 
treatment effect was significantly lower in high 
accumulating brain regions (49 ± 11%) when 
compared to brain regions with low accumulation, in 
which there was a relative treatment effect of 69 ± 28% 
(p < 0.05, Figure 5E). Kinetics of accumulation in 
individual animals to serial PET measurements in 
high and low Aβ accumulating regions are presented 
in Figure S3. 
We find significant regional differences in the 
response to chronic BACE1 inhibition treatment, 
which is characterized by a linear relationship relative 
to vehicle treatment. Regions with more pronounced 
fibrillary Aβ deposition are characterized by greater 
resistance to BACE1 inhibition, whereas a 100% 
blocking was achieved in regions with low deposition 
rates, all relative to findings in the vehicle group. The 
finding of individual deposition rate thresholds for 
complete blocking of Aβ deposition by a theranostic 
concept might guide individual dose regimens for 
BACE1 inhibitors in future clinical studies. Optimal 
dosing for blockade in high accumulating regions 
must be assessed in the light of a possible trade-off 
between side effects and clinical efficacy.  
BACE1 inhibition treatment is more effective 
during early amyloid build-up 
The serial Aβ-PET design made possible an 
assessment of baseline plaque load in brains of 
individual mice prior to initiation of the treatment. 
We used this technique to predict differences in 
longitudinal fibrillary Aβ deposition from 
the baseline level, based on our earlier 
findings of such an association [15]. Indeed, 
present findings in TG-VEH mice indicated 
an inverse association between baseline Aβ 
burden and the relative increase from 9.5 to 
13.5 months of age (R = -0.53, p < 0.05; 
Figure 6A). Thus, TG-VEH mice starting at a 
low baseline Aβ-level tended to catch up 
their initially delayed Aβ accumulation. 
TG-BSI mice revealed the highest 
treatment-related difference relative to the 
TG-VEH group when their initial Aβ-level 
was low, as the accelerated increase 
observed in vehicle animals was prevented, 
leading to a reversal in the direction of the 
correlation (R = +0.27, p = n.s.; Figure 6A). 
In those TG-BSI mice with high Aβ-levels to 
baseline PET, the treatment effect was 
hardly discernible from the TG-VEH group. 
Findings in representative mice with a 
nearly equal baseline amyloidosis are 
illustrated in Figure 6B. To confirm the 
“regular” inverse correlation between 
baseline Aβ-level and the subsequent 
deposition rate, we longitudinally imaged 
another vehicle-treated TG group (N=12), 
which confirmed the above results 
(RBL/∆%-BL-TER = -0.58, p < 0.05). 
The finding that baseline PET results 
predict treatment efficacy indicates that 
therapeutic BACE1 inhibition should be 
obtained early in the pathology time course, 
as present amyloid deposits proved more 




Figure 6. Treatment effect dependency from baseline amyloidosis. (A) Response 
prediction by means of Aβ-PET. The percentage increase from baseline to termination SUVRCTX/WM is 
depicted as a function of the individual baseline value. For the TG-BSI, a low baseline value predicted 
a lesser increase in amyloidosis during treatment, whereas TG-VEH mice with a low baseline value 
increased tremendously. The treatment effect in TG-BSI relative to TG-VEH was markedly lower 
when amyloidosis was already established. The correlations (R) between the percentage increase and 
the baseline value are indicated. (B) Aβ-PET signal intensities of individual exemplary mice for serial 
baseline, follow-up and terminal imaging time-points. The TG-BSI mouse with a low baseline (#20) 
indicates a very low Aβ accumulation whereas the TG-VEH mouse with a low baseline (#08) shows 
high Aβ accumulation. TG-BSI and TG-VEH with a high baseline show only minor differences in their 
sequential Aβ accumulation. Coronal and axial slices are illustrated upon a T1w MRI template. 






In this adequately powered longitudinal PET 
study of cerebral amyloidosis in a transgenic AD 
mouse model we investigated regional effects of a 
chronic disease-modifying therapy based on BACE1 
inhibition by applying a theranostic concept. The 
molecular imaging study entailed corroborative 
histopathological as well as biochemical analyses, 
thus encompassing three different readout modalities 
for monitoring amyloidogenesis. 
Serial [18F]-florbetaben Aβ-PET in PS2APP 
mice provides a robust method for monitoring 
anti-amyloid treatment effects 
Serial Aβ-PET excellently captured the treatment 
effects of BACE1 inhibition versus vehicle and 
allowed in vivo assessment of the therapeutic target in 
individual mice. A recent study using a multi-tracer 
design succeeded in monitoring BACE1 effects in an 
amyloid mouse model using another Aβ-PET ligand 
([18F]-florbetapir), although the similarly altered 
signal in treated WT mice led the authors to conclude 
that the observed binding effects were not specific 
treatment effects on amyloid deposition [22]. In 
contrast, we found a highly stable background signal 
in WT mice in treatment and vehicle groups using the 
amyloid ligand [18F]-florbetaben, which encourages 
the use of the mouse model in combination with the 
earlier-validated quantification method [16]. A recent 
PET study showed the ability to detect non-fibrillar 
Aβ forms in vivo during treatment of transgenic 
ArcSwe mice with another BACE1 inhibitor [23], 
whereas our PET ligand binds only fibrillary parts of 
the plaque. Future monitoring regimes could 
therefore entail dual PET with selective tracers to 
capture both components of amyloidosis during 
BACE1 inhibition.  
Linear dependence of BACE1 inhibition 
treatment effect from Aβ deposition rates can 
be captured by individual serial imaging 
In the present study with the BACE1 inhibitor 
RO5508887 at a daily dose of 100 mg/kg, we obtained 
only 49% attenuation of progression in brain regions 
with high Aβ deposition, suggesting that a higher 
dose might have been more efficacious. The APP-Swe 
transgenic mouse model, given its high rate of Aβ 
synthesis, presents a clear limitation arising from the 
need for relatively high inhibitor dosing. However, 
more recent data have indicated a dose-dependent 
impairment of synaptic plasticity and cognitive 
functions or reduced muscle spindle numbers in adult 
mice with chronic BACE1 inhibitor treatment, which 
could be attributed to impairing function of the 
BACE1 substrate Neuregulin-1 [24, 25]. Thus, there is 
need for caution in selecting dosage regimens for 
drugs targeting BACE1 aiming to achieve a 
therapeutic window with optimal trade-off between 
safety and efficacy. The current data provide evidence 
that regional efficacy of RO5508887 treatment linearly 
correlates with the regional naïve deposition rate 
revealed by Aβ-PET in vehicle-treated animals. Thus, 
prior knowledge of the individual Aβ deposition rate 
might inform the estimation of an optimal dosage of 
BACE1 inhibitor to slow or even arrest further 
progression of cortical fibrillary amyloidosis. This 
issue is even more important when considering the 
clinical finding that Aβ accumulation rates in 
amyloid-positive humans are very heterogeneous [26, 
27]. Such a treatment design and combinatorial 
treatments together, e.g., with an Aβ immunotherapy 
strategy might require dosage titration of BACE1 
inhibitors in individual patients according to their 
individual amyloidosis rates at initiation of therapy. 
Harkening back on the potential for cognitive side 
effects, it could well be that there are patients for 
whom the BACE1 inhibitor dosage predicted to be 
effective for slowing amyloidosis would bring an 
excessively high risk for adverse effects. On the other 
hand, some patients might require only low doses of 
BACE1 inhibitors, either because of their earlier 
disease stage, or an intrinsically lower Aβ 
progression. In this regard, recent detailed PET study 
of amyloid accumulation rates of humans with 
preclinical AD revealed a strong global and regional 
variation, which has major implications for 
anti-amyloid trials [28]. Our current findings of high 
and low amyloid accumulating regions in PS2APP 
mice are in line with the human findings, which 
emphasizes that our novel preclinical approach for 
dose-titration by considering amyloid deposition 
rates in multiple brain regions might be translatable to 
human investigations. Serial Aβ-PET therefore has the 
potential to serve as a readout for determining the 
individual dosage as well as for monitoring 
effectiveness of treatment in individual patients in the 
context of personalized medicine.  
Early treatment initiation ensures high efficacy 
in BACE1 inhibition treatment 
Current results constitute compelling evidence 
that efficacy of RO5508887 in individual TG mice 
receiving a predefined dose of the medication 
depends on their fibrillary individual Aβ levels at 
therapy initiation, as is revealed by baseline Aβ-PET. 
By selecting the present dose of 100 mg/kg/d 
RO5508887 on the basis of earlier findings [17] and by 
single dose validation in the current model, we 
observed a greater benefit in those mice having a 
relatively low plaque load at baseline, which matches 





findings in our previous study with a gamma 
secretase modulator in Swedish mutant mice [15]. 
Thus, the relationship emerges as a general principle, 
irrespective of the molecular target in a treatment 
intervention. We now show that BACE1 
inhibitor-treated mice with high and low baseline 
amyloid levels progressed equally, whereas the 
course in vehicle mice with low Aβ to baseline PET 
clearly had a more pronounced increase of 
amyloidosis between 9.5 and 13.5 months of age. This 
concept is coherent in the light of our 
immunohistochemistry findings, since the major 
impact of BACE1 treatment was clearly observed in 
lowering the fraction of small plaques. Thus, this 
treatment evoked the anticipated molecular effect on 
de novo plaque formation [17]. Findings of a recent 
chronic treatment study using a different BACE1 
inhibitor and a different amyloid mouse model are in 
line with our terminal immunohistochemistry results 
as their images indicated a similar main treatment 
effect on small plaques [22]. In summary, we find that 
the present dosage of RO5508887 can substantially 
lower the progression of amyloidosis in those brain 
regions and in those individual animals with low 
pre-existing plaque load. Due to the logistic difficulty 
and cost of serial PET imaging, we only investigated 
one preselected dosage and only one starting age. 
However, higher doses and persistent inhibition 
achievable, e.g., by oral drug administration with 
food would be necessary if the treatment initiation 
were at a disease stage with established plaque 
deposition. It remains to be elucidated if sufficient 
RO5508887 doses for such cases can be administered 
without provoking treatment-limiting side effects. 
While our present results in a double transgenic 
β-amyloid mouse model are not immediately 
translatable to clinical AD, we provide compelling 
evidence that Aβ-PET can potentially inform a crucial 
decision for clinical AD trials: at what stage of AD 
should BACE inhibitors be administered? With 
precisely this in mind, cortical Aβ levels are being 
examined in current phase II/III trials of BACE 
inhibitors [12]. Very recently, two phase III trials with 
Lanabecestat were discontinued early as they would 
probably not have met their primary endpoints [29]. 
Full details on the reasons behind the decisions are 
not yet released, but there is a general opinion that 
BACE1 inhibitors are unlikely to be effective in 
individuals who already have symptoms of AD 
dementia [29]. Our current results of lesser efficacy in 
mice with established amyloidosis give the first 
PET-based in vivo evidence for this contention. It will 
be of enormous interest if the efficacy in human 
treatment indeed proves to be predictable from the 
state of cortical amyloidosis at initiation of treatment. 
The lack of behavioral testing in this study presents a 
limitation since we can make no claims about 
beneficial or detrimental effects on cognition in the 
treated mice.  
Conclusion 
We demonstrate that serial Aβ-PET in PS2APP 
mice provides a robust theranostic approach for 
monitoring BACE1 inhibition treatment effects in this 
adequately powered longitudinal study. Regional 
analyses indicated a linear dependence of treatment 
efficacy upon Aβ deposition rates in the 
vehicle-treated group. Serial Aβ-PET could therefore 
serve as a readout for titrating the optimal individual 
dosage as well as for monitoring treatment 
effectiveness in the context of personalized medicine. 
Finally, the correlation between baseline and the 
individual treatment effects in conjunction with 
terminal histological results revealed the need of an 
early BACE1 treatment initiation for prevention of de 
novo amyloidogenesis. 
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